

Partnership. Innovation. Passion.

October 18, 2023

To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai: 400 001

To, The Manager – Listing, National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai: 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sirs,

Sub: Statement of Investor Complaints

Pursuant to Regulation 13 (3) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find below the statement of Investor complaints for the quarter ended September 30, 2023:

Sr. No	Particulars	Details
1	No. of Investor Complaints pending at the beginning of the quarter	00
2	No. of Investor Complaints received during the quarter	01
3	No. of Investor Complaints disposed off during the quarter	01
4	No. of Investor Complaints those remaining unresolved at the end of the	
	quarter	00

Please take the same on records.

Yours faithfully,

For Glenmark Life Sciences Limited

Rudalf Corriea Company Secretary & Compliance Officer

Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400 099, India. Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com W: www.glenmarklifesciences.com